p53 mutations in urinary bladder cancer by Berggren, P et al.
The human tumour suppressor gene p53 maps to chromosome
17p13.1, consists of 11 exons spanning over 20 kb of DNA and
encodes for a 393 amino acids, 53kDa nuclear protein (Lane and
Crawford, 1979; Isobe et al, 1986). The p53 protein has several
biological functions such as involvement in cell cycle regulation,
programmed cell death, senescence, differentiation and develop-
ment, transcription, DNA replication, DNA repair and mainte-
nance of genomic stability (Hainaut and Hollstein, 2000). Genetic
changes in the p53 gene are found in almost every kind of human
cancer (Hainaut et al, 1998; Hainaut and Hollstein, 2000). Missense
mutations can induce alterations in the tertiary structure of the
protein, thereby interfering with the ability of p53 to bind to recog-
nition sequences (Kern et al, 1991) and/or activate transcription
(Fields and Jang, 1990; Raycroft et al, 1990). Mutations are diverse
in localization and nature; even though mutations are found
outside the evolutionary conserved regions, the majority of point
mutations are located within these (exons 5–8) (Greenblatt et al,
1994; Hainaut and Hollstein, 2000). 
Urinary bladder neoplasms are the forth most common
neoplasm in men in the Western world (Knowles, 1999b). The
incidence in Sweden is about 32 for men and 9 for women per 105
person-years (approximately 1500 and 600 cases, respectively)
(Centre for Epidemiology, 1998). Almost all bladder cancers 
in Western countries are transitional cell carcinomas (TCC).
Cigarette smoking, industrially related aromatic amines and 
exposure to the drugs phenacetine, chlornaphrazine and
cyclophosphamide, are connected to TCC occurrence (IARC,
1985; Steineck et al, 1995; Cohen et al, 2000). Underlying molec-
ular defects involve the activation of oncogenes and inactivation
of tumour suppressor genes and many genetic alterations have
been identified, of which some of the affected genes are p53, p16,
p14ARF, PTEN, PTCH, DBCCR1 and RB (Knowles, 1999a). The
histopathological classification has recently been the subject of an
intense debate. After initial work by, for example, Bergqvist et al
(1965) and Esposti and Zajicek (1972), some centres have modi-
fied the WHO grading system to distinguish grade 2a and grade 
2b tumours, the outcome between these subgroups differ markedly
in some series (Malmstrom et al, 1987; Malmstrom, 1988; Carbin
et al, 1991). Recently an international group of pathologists
suggested that moderately differentiated (G2) urinary bladder
neoplasms should be either categorized as lowly or highly malignant
(Epstein et al, 1998). The proposed division is similar, if not iden-
tical, to the previously described distinction between G2a and G2b.
Previous studies of p53 mutations in urinary bladder neoplasms
have reported mutation frequencies between 6% and 61%
(Shipman et al, 1997; Sidransky et al, 1991). The diverse frequen-
cies are to some extent determined by variations in the tumour
stage and grade: a much higher number of mutations are found in
tumours of high stage and grade than in tumours of low stage and
grade (Fujimoto et al, 1992). We have analysed the p53 mutational
spectra for urinary bladder neoplasms by studying the mutation
frequency in exons 5–8 of the p53 gene in a material consisting of
TCCs of various stage and grade. We used a highly sensitive
multiplex-PCR and fluorescent SSCP method for mutation
screening followed by sequencing for confirmation and identifica-
tion of mutations. Analyses of the mutational spectra for the p53
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mutations and the role that p53 inactivation plays in urinary
bladder cancer. 
MATERIALS AND METHODS 
Tumour tissues from almost all newly diagnosed cases of urinary
bladder cancer during the years 1995 and 1996 were collected in
the Stockholm area. We have more than 600 cases, which are
almost all cases that occurred in the area at the time. Of the total
number of urinary bladder neoplasms collected, 189 samples were
selected from cases where corresponding normal tissue and aetio-
logical information was available. None of the patients had been
given prior treatment before analysis. All cases were screened for
mutations and polymorphisms, using multiplex-PCR fluorescent
single-strand conformation polymorphism (M-PCR-F-SSCP),
between the regions coding for exons 5–8 of the p53 gene. Base
changes present in both normal and tumour tissues at a frequency
higher than 1% were defined as polymorphisms; changes present
in tumour tissue only were defined as mutations. Samples positive
for mutations or polymorphisms were sequenced twice from
separate PCRs to exclude artefacts. 
Patients and tissue 
Tumours were removed with transurethral resection. 4 tissue
samples were taken with cold cup biopsy and snap frozen in –80˚C
before removal. Frozen tissues were cut in approximately 5 mm
thick sections. The first and last sections were stained and exam-
ined for tumour contents by a pathologist. Only biopsies with more
than 70% tumour cells were included in the present analysis.
Tumour DNA was extracted by a previously described method
(Sambrook et al, 1989). All tumours were staged and graded.
Stage was assessed according to the TNM-system (Hall and Prout,
1990). All muscle invasive tumours were analysed together.
Grading was done according to Bergkvist (Bergkvist et al, 1965).
Stage and grade information was available for 188 of the 189
bladder neoplasms and distributed as follows: Tis: 3 (1.6%), Ta:
106 (56%), T1: 29 (15%) and ³T2: 50 (27%). G1: 10 (5%), G2a:
78 (41%), G2b: 33 (18%), G3: 64 (34%) and G4: 3 (1.6%).
Combined information gives 82 (44%) lowly malignant neoplasms
(Ta, G1–G2a) and 106 (56%) high-grade (G2b–G4) or invasive
(³T1) highly malignant neoplasms. From each patient venous
blood was drawn into EDTA tubes and frozen. DNA was extracted
as previously described (Wada et al, 2000). 
Multiplex PCR and fluorescent SSCP 
We used a mutation screening method developed in our laboratory,
detailed PCR-SSCP conditions and primer sequences have been
previously described (Berggren et al, 2000b). In short, exons 5–8 of
the p53 gene were amplified in a single PCR reaction and then
loaded onto native SSCP gels using different conditions and an ABI
377 (PE Biosystems). Mutations and polymorphisms were detected
as mobility shifts. All mobility shifts were sequenced with
DyeDeoxy terminator cycle sequencing. Thermosequenase 2.0
(Amersham Pharmacia Biotech) or Big Dye (PE Biosystems)
sequencing kits were used according to the manufacturer’s instruc-
tions. Putative mutations were confirmed on both coding and
noncoding strands from a new PCR reaction. The sample with a
deletion (K105) was reamplified in a radioactive PCR and loaded
onto a slab gel from which the band-shift was excised and sequenced. 
Detection of LOH 
Cases in which both tumour and normal tissue were available 
(175 patients) were analysed for loss of heterozygosity (LOH). 
2 markers were used: the p53 exogenic (CA)n dinucleotide and the
intragenic (intron one) (AAAAT)n pentanucleotide repeat poly-
morphisms. Tumour-and normal DNA was amplified using previ-
ously reported primers and PCR conditions (Futreal et al, 1991;
Jones and Nakamura, 1992). PCR fragments, labelled with Cy-5,
were loaded onto a denaturing (9 M urea), 6% acrylamide gel, run
for 80 minutes at 900 V, 40 mA, 20 W and 45˚C in 1 ´ TBE buffer
using an ALF express machine (Amersham Pharmacia Biotech).
Size markers of 100 and 150 base pairs were included in the gel.
LOH was defined as a reproducible reduction of at least 30% of
either the smaller or larger allele. Samples that were homozygous
for the marker were defined as non-informative and excluded from
calculations for LOH frequency. All samples where LOH was
found were re-analysed from a new PCR. 
Statistical calculations 
The correlations between mutation and LOH versus stage (Tis, Ta,
T1 and ³T2) and grade (G1, G2a, G2b, G3 and G4) were done
with regression analysis using Microsoft Excel 97. The relation-
ships between mutation and LOH versus lowly malignant tumours
(Ta, G1–G2a) and highly malignant tumours (G2b–G4 and ³T1)
where calculated with a c2 test using EPI6 (CDC, USA and WHO
Geneva, Switzerland). 
RESULTS 
In the 189 samples analysed, 31 mutations in 26 patients (14%)
and 32 polymorphisms were found, all mutations are shown in
Table 1. One of 82 patients (1.2%) with a lowly malignant tumour
(Ta, G1–G2a) had a p53 mutation as did 25 of 106 (24%) with a
high-grade (G2b–G4) or invasive (³T1) tumour. Tumour stage and
grade were associated to p53 mutation and LOH of both the (CA)n
repeat and the (AAAAT)n repeat. Lowly malignant neoplasms had
a lower percentage of LOH (12%, 12%) than highly malignant
neoplasms (30%, 43%) for both the (CA)n repeat and the
(AAAAT)n repeat. 
Mutations 
22 of the mutations were transitions, 16 G:C ® A:T and 6 A:T ®
G:C. 8 mutations were transversions, 6 G:C ® C:G, one G:C ® T:A
and one A:T ® T:A. No A:T ® C:G mutations were found. 7 muta-
tions were in exon 5, 5 in exon 6, 7 in exon 7 and 12 in exon 8. 3 were
silent, 22 were missense mutations, 5 were nonsense mutations and
one mutation was a deletion. The 6 base pairs deletion was found in
exon 7, in the same allele as the deletion and right next to it, there 
was also a point mutation. 4 of the 5 nonsense mutations were found
in exon 6. A silent mutation in codon 153 was present in both normal
and tumour tissue and has been reported by others as a silent
mutation found in tumour tissue only, we therefore believe that the
one found by us is a germline mutation (Lohmann et al, 1993;
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we found in codons 153, 171, 197, 239, 245, 247, 281, 286 and 291
have not been previously reported for urinary bladder cancer, though
all the mutations, but the ones in codons 171 and 247, have been
reported for other cancer types (Hainaut et al, 1998). 2 samples had
double missense mutations, one sample with 2 mutations in exon 5
and one sample with a mutation in exon 7 and 8. One sample had 3
mutations, all 3 G:C ® A:T transitions, in exon 8 in codons 285, 287
and 291. The codon 285 mutation was a missense mutation but
the other 2 were silent. Representative SSCP results are shown in
Figure 1. 
Polymorphism 
32 polymorphisms were found. 3 of them were A:T ® G:C transi-
tions at codon 213 in exon 6 (Carbone et al, 1991), occurring at a
frequency of 1.6%. Moreover 29 were linked C:G ®T:A and T:A ®
G:C polymorphisms (24 of these have been previously reported
(Berggren et al, 2000a)) in intron 7 at base positions 14181 and
14201 (Prosser and Condie, 1991) (genebank accession no. X54156)
occurring at a frequency of 15%. 
LOH 
14 of the tumour samples were excluded from LOH analysis
because there was no normal tissue available. 2 samples analysed for
the (CA)nmarker failed. 58 (34%) of the 173 samples analysed for the
(CA)n repeat were homozygous and thus not informative for 
the marker. Of the 115 (66%) informative samples 90 (78%)
retained heterozygosity and 25 (22%) showed LOH. 72 of the 175
samples analysed for the (AAAAT)n repeat were homozygous. Of
the 103 (59%) informative samples, 72 (70%) retained heterozy-
gosity and 31 had LOH (30%). 43 (29%) of the samples informa-
tive for at least one of the repeats showed LOH for one or both
repeats. Only one sample with LOH for the (CA)n repeat retained
heterozygosity for the (AAAAT)n repeat whereas 8 samples that
had LOH for the (AAAAT)n repeat retained heterozygosity for the
(CA)n repeat. 
Mutation and LOH 
For 4 of the mutated samples there was no normal tissue available. 7
of the mutated samples showed LOH for the (CA)n repeat, 10 were
not informative and 5 samples retained heterozygosity. 10 of the
mutated samples showed LOH for the (AAAAT)n repeat, 9 were not
informative and 3 samples retained heterozygosity. One sample
informative but without LOH for the (CA)n repeat showed LOH for
the (AAAAT)n repeat. There were 3 mutated samples that were
informative but without LOH for both repeats. One of these samples
had double mutations (exon 7 and 8), one had a silent mutation
(codon 153) and the third sample was the only mutated sample that
was of both low grade and low stage. In 31 samples (21% of all
samples informative for at least one of the repeats) showing LOH
for either the (CA)n or the (AAAAT)n repeat, or both repeats, we
could not find any mutations in any of the exons 5, 6, 7 or 8. 
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Table 1 Mutations, loss of heterozygosity, stage and grade 
Sample Exon Codon Change Triplet Amino  acid (CA)n (AAAAT)n Stage Grade 
K131 5 163* A®GT A C ®TGC Tyr®Cys I I Ta G2a 
SS11 5 153** C®T CCC®CCT Pro®Pro I I Ta G2b 
K37 6 196 STOP C®T CGA®TGA Arg®OPA NI NI Ta G2b 
D36 6 192 STOP C®T CAG®TAG Gln®AMB NI NI Ta G3 
K95 7 245 G®C GGC®CGC Gly®Arg NTNA NTNA Ta G3 
H33 8 281 G®C GAC®CAC Asp®His LOH LOH Ta G3 
S139 6 192 STOP* C®T CAG®TAG Gln®AMB NI LOH T1 G3 
K130 6 213 STOP* C®T CGA®TGA Arg®OPA LOH LOH T1 G3 
D35 7 236 A®GT A C ®TGC Tyr®Cys LOH NI T1 G3 
S77 7 239 A®G AAC®AGC Asn®Ser LOH LOH T1 G3 
K105 7 247(14066) A®G AAC®GGG Asn®Gly NI NI T1 G3 
14067-72 ACCGGA -6bp Deletion
K111 7 248 C®T CGG®TGG Arg®Trp I I T1 G3 
8 280 G®A AGA®AAA Arg®Lys 
S111 7 248 G®A CGG®CAG Arg®Gln NI LOH T2 G2a 
K119 5 171* G®C GAG®CAG Glu®Gln NI NI T2 G2b 
5 175* G®A CGC®CAC Arg®His 
K94 8 280 G®C AGA®ACA Arg®Thr NTNA NTNA T2 G2b 
K62 5 163 A®GT A C ®TGC Tyr®Cys LOH LOH T2 G3 
K140 5 179* A®GC A T ®CGT His®Arg NI LOH T2 G3 
K48 5 179 C®TC A T ®TAT His®Tyr LOH NI T2 G3 
H48 6 197 G®A GTG®ATG Val®Met LOH LOH T2 G3 
S174 8 273 G®A CGT®CAT Arg®His I NI T2 G3 
S104 8 280 G®A AGA®AAA Arg®Lys NI NI T2 G3 
S37 8 283 G®C CGC®CCC Arg®Pro NTNA NTNA T2 G3 
H51 8 285 A®T GAG®GTG Glu®Val NTNA NTNA T2 G3 
S27 8 286 G®T GAA®TAA Glu®OCH I LOH T2 G3 
D79 8 280 G®C AGA®ACA Arg®Thr NI NI T2 G4 
D60 8 285 G®A GAG®AAG Glu®Lys NI LOH T2 G4 
287 G®A GAG®GAA Glu®Glu 
291 G®A AAG®AAA Lys®Lys 
*The mutation has been previously reported (Berggren et al, 2000b), **Germline mutation. I = informative, NI = not informative, LOH = loss of heterozygosity,
NTNA = normal tissue not available. Stage and grade versus mutation 
A higher proportion of mutations was found in tumours of high
stage or grade than in tumours of low stage or grade. The corre-
lation is shown in Figure 2, panelsA and B. Tis: 0/3 (0%), Ta:
6/106 (6%), T1: 6/29 (21%) and ³ T2: 14/50 (28%) (P = 0.02).
G1: 0/10 (0%), G2a: 2/78 (3%), G2b 4/33 (12%), G3: 18/64
(28%) and G4: 2/3 (67%) (P = 0.03). Stage and grade informa-
tion taken together show that lowly malignant tumours (Ta,
G1–G2a) carry fewer mutations (1/82 = 1.2%) than highly
malignant tumours (high grade (G2b–G4) or invasive (³ T1))
where 25 of 106 (24%) had p53 mutations (P = 0.00001). 
Stage and grade versus LOH 
A higher number of tumours of high stage or grade had loss of
heterozygosity for the (CA)n repeat than did tumours of low stage or
grade. Tis: 0/2 (0%), Ta: 11/66 (17%), T1: 6/22 (27%), ³T2: 8/25
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A    Exon 5
C    Exon 7
B    Exon 6









Figure 1 Representative pictures from SSCP electropherograms for the 4 amplified fragments, p53 exons 5–8. Top panels show
tumour tissues and lower panels show wild-type tissues. Arrows point at additional peaks. Panel A is sample K119, B is sample D36,
C is sample K105 and D is sample D60. SSCP conditions for panels A and B were 0.6 ´ MDE with 5% glycerol run at 33˚C and
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Figure 2 Correlation between stage, grade, mutations and loss of
heterozygosity. Panels A and B show mutations on y-axis and stage and
grade on x-axis. Panels C–D show LOH for the (CA)n repeat on the y-axis
and stage and grade on the x-axis. Panels E–F show LOH for the (AAAAT)n
repeat on the y-axis and stage and grade on the x-axis(32%) (P = 0.03). G1: 0/5 (0%), G2a: 6/50 (12%), G2b: 4/22 (18%)
and G3: 15/38 (39%) (P = 0.03). None of the G4 tumours were infor-
mative for the (CA)n repeat. The observation that was made for the
(CA)n repeat and LOH was also true for the (AAAAT)n repeat. Tis:
0/2 (0%), Ta: 10/56 (18%), T1: 8/19 (42%), ³ T2: 13/26 (50%) (P =
0.01). G1: 0/7 (0%), G2a: 6/40 (15%), G2b: 7/18 (39%), G3: 16/36
(44%) and G4: 2/2 (100%) (P = 0.02). The correlation between LOH
and tumours of high stage and grade is shown in Figure 2, panels
C–F. Combined stage and grade information shows that 6/51 (12%)
of lowly malignant tumours had LOH for the (CA)n repeat compared
to 19/64 (30%) of highly malignant tumours (P = 0.02). 5 out of 43
(12%) lowly malignant tumours had LOH for the (AAAAT)n
repeat compared to 26/60 (43%) of highly malignant tumours 
(P = 0.0006). 
DISCUSSION 
We found a clear distinction between G2a and G2b urinary bladder
neoplasms concerning the occurrence of genetic events related to
p53. Virtually no mutations (exons 5–8) occurred in TaG1–G2a
tumours. Overall we discovered 31 p53 mutations in 26 patients
(14%) in 189 analysed bladder neoplasms and depending on the
used marker, LOH was found in 22% and 30% of informative
cases. A substantial part of urinary bladder neoplasms showed no
genetic alterations in p53. Only one mutation (1.2%) was found in
a lowly malignant tumour (Ta, G1–G2a) whereas 25 (24%) of
invasive (³T1) or high grade (G2b–G4) tumours were mutated.
This is the first series (to our knowledge) relating the occurrence
of a genetic event in p53 to the refined grade categories 2a and 2b.
Our data support the notion that moderately differentiated bladder
neoplasms are genetically heterogeneous and that it may be bene-
ficial to abandon the present WHO category, as suggested by an
international panel of pathologists (Epstein et al, 1998). 
The Li–Fraumeni syndrome, associated with an inherited p53
mutation, has a very low rate (in the vicinity of 1%) of urinary
bladder neoplasms, which suggests that a p53 mutation is more
likely to be a late event in bladder tumour progression than an
initiator of malignant transformation (Kleihues et al, 1997; Varley
et al, 1997). Other studies of urinary bladder cancer have reported
mutation frequencies for p53 from 6% to 61% (Sidransky et al,
1991; Shipman et al, 1997) and most studies have found higher
mutation frequencies than we did. Where most published studies
have focused on tumours of high stage and grade, our patient series
presented many tumours of low stage and grade. 
We found more transitions than transversions. The most
common mutation was the G:C®A:T transition which can occur
both by spontaneous deamination of 5-methylcytosine to thymine
and factor mediation, e.g., through oxygen radicals or nitric oxide
(Lindahl, 1979). Although urinary bladder cancer has a strong
association with cigarette smoke we found only one G:C®
T:A transversion, a mutation present at an increased frequency in
lung cancers among smokers (IARC, 1985; Bennett et al, 1999).
Reported series of urinary bladder cancer shows 14% of
G:C®C:G transversions, 12% G:C®T:A transversions and 19%
of A:T®G:C transitions; we found 19%, 3% and 10% respectively
(Hollstein et al, 1998). We did not find any A:T®C:G transver-
sions, but this mutation has a low overall frequency (3%) and we
only found one deletion (3%), which is less than in reported series
(10%) (Hollstein et al, 1998). We found 6 mutations at CpG sites
(19%), which is lower compared to other cancers (23%) but in
agreement with previously reported series for urinary bladder
(18%). However, urinary bladder neoplasms caused by endemic
schistosomal infection (mainly squamous cell carcinoma) have a
higher reported frequency of CpG mutations (Warren et al, 1995;
Hainaut and Hollstein, 2000). One sample had 3 mutations in exon
8, this sample also showed LOH for the (AAAAT)n repeat indi-
cating that all the 3 mutations were in the same allele. All 3 muta-
tions were G:C®A:T transitions located in exon 8 between codons
285 and 291 and probably caused by the same mutational event. 4
mutations (13%) were found in codon 280 and 2 (6.5%) in codon
285, these 2 codons have been previously reported as mutational
hot spots for urinary bladder cancer (Spruck et al, 1993; Xu et al,
1997). In the p53 database, where over 10 000 p53 mutations have
been reported, the codon 280 mutation makes up for 1.2% of all
reported mutations but 5.1% of urinary bladder cancer mutations
(Hainaut et al, 1998). Moreover, gallbladder has 8% of codon 280
mutations and neoplasms in the urinary system 2.7%. No other
cancer, where at least 50 mutations have been reported totally, has
a frequency over 2% for codon 280 mutations. Mutations in codon
285 represent 0.8% of mutations in all cancers but 4.3% of urinary
bladder cancer mutations. 
31 samples (21%) informative for one or both markers showed
LOH for either the (AAAAT)nrepeat or the (CA)nrepeat but were not
mutated in any of the exons 5–8. Although SSCP does not guarantee
100% mutation detection, the SSCP method we used has been previ-
ously evaluated in 4 different gels screening for known mutations and
had a sensitivity of over 90% (Berggren et al, 2000b). Following
Knudson’s ‘two-hit’ hypothesis (Knudson, 1971), one could expect a
mutation in exons that were not analysed in this study or mutations in
distant splice sites and promoter regions. This seems unlikely consid-
ering that the mutation frequency for exons 2–4 and 9–11 is much
lower than for exons 5–8 (Miyamoto et al, 1993; Lianes et al, 1994;
Williamson et al, 1994; Hainaut and Hollstein, 2000) and that 31
samples had LOH but no mutation. Another explanation could be a
second tumour suppressor gene on chromosome 17p13 such as the
suggested tumour suppressor gene HIC-1 (Wales et al, 1995). LOH
has also been reported at 17p13.3 for various types of cancer
including breast and ovarian cancer (Coles et al, 1990; Schultz et al,
1996). It is also possible that the allelic loss at chromosome 17p13.1
may precede the p53 gene mutation as suggested by others for
chronic myelogenous leukaemias (Feinstein et al, 1991; Nakai et al,
1992). However, since the (AAAAT)n repeat is intragenic to p53, it is
unlikely that this marker would reflect another tumour suppressor
gene and the most possible explanation for our findings is that other
mechanisms than point mutations inactivate p53. It is likely to
believe that genes upstream or downstream of p53 have been inacti-
vated, such as MDM2 and  p14ARF, thereby disrupting the p53
pathway. Moreover, loss or inactivation of the wild-type allele is not
always required for disruption of p53 function; a number of mutants
can inactivate wild-type p53 in a dominant manner so that the mutant
p53 can oligomerize with wild-type p53 to form an inactive complex
(Hainaut and Hollstein, 2000). 
Although only 14% of the analysed samples carried mutations,
30% showed LOH for the intragenic (AAAAT)n repeat suggesting
that p53 is affected in urinary bladder cancer also through mecha-
nisms other than mutations. To understand the pathogenesis and
cancer aetiology of urinary bladder cancer, further studies of other
key components in the cell cycle machinery, for example the genes
p16, p14ARF and  RB are required in large population based
materials. Our data support that grade 2a tumours, recently
suggested to be renamed as grade 1, seldom harbour a p53
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than grade 2b–4 urinary bladder neoplasms – which in many cases
harbour a p53 mutation, allele loss and possibly some other
genetic event that results in a dysfunctional p53 protein. 
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